Trials / Completed
CompletedNCT02636595
The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)
A Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 121 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effect of response to treatment by evaluating the percentage of subjects achieving a 12-week sustained virologic response (SVR12) after 12 weeks of treatment with ABT-493/ABT-530 and to evaluate the safety of the regimen in participants with chronic hepatitis C virus (HCV) genotype (GT) 4, 5, or 6 infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-493/ABT-530 | Tablet; ABT-493 coformulated with ABT-530 |
Timeline
- Start date
- 2015-11-01
- Primary completion
- 2016-10-01
- Completion
- 2017-01-01
- First posted
- 2015-12-22
- Last updated
- 2021-07-13
- Results posted
- 2017-09-14
Source: ClinicalTrials.gov record NCT02636595. Inclusion in this directory is not an endorsement.